PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Naoki Fujimoto

Division of Respiratory Medicine, Center for Respiratory Diseases, NHO Kyoto Medical Center, Kyoto, Japan.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUL 27, 2026 · JOURNAL ARTICLE

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Lung Cancer Management

Small retrospective single-centre case series (n=11) describing treatment sequences and outcomes in ALK-positive NSCLC, with descriptive efficacy and safety data but no comparator group and high risk of selection bias.

PreliminarySaiki Yoshimura Molecular Target Therapy Shogo Toyama

Reported

Sample size11

Median age59 years

Female patients5 (45.5%)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support